Report - MAMMACARCINOM – UPDATE NIO-KONGRESS 2017nio-kongress.de/wp-content/uploads/2017/02/20170204_Lueck_Mam… · cT1: 11%, cN0: 42% cT1: 26%, cN0: 60% Control therapy Sequenced Concurrent

Please pass captcha verification before submit form